Synthesis and biological activity of selective azasugar-based TACE inhibitors.
暂无分享,去创建一个
Shin-Ichiro Nishimura | Hirosato Kondo | Yoshimasa Inoue | Kohichiro Yoshino | Takahiro Tsukida | Hideki Moriyama
[1] A. H. Drummond,et al. Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.
[2] Synthesis and structure-activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids as HB-EGF shedding inhibitors. , 2003, Bioorganic & medicinal chemistry.
[3] K. Tracey,et al. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.
[4] P. McCann,et al. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.
[5] Hirosato Kondo,et al. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids. , 2002, Journal of medicinal chemistry.
[6] R. Bast,et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.
[7] S. Nishimura,et al. Structure--activity relationships of azasugar-based MMP/ADAM inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[8] M. Sanner. Selective dopamine D4 receptor antagonists , 1998 .
[9] A. H. Drummond,et al. Recent advances in matrix metalloproteinase inhibitor research , 1996 .
[10] R. Black,et al. Adamalysins: A Family of Metzincins Including TNF‐α Converting Enzyme (TACE) , 1999 .
[11] James M. Chen,et al. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups. , 2002, Bioorganic & medicinal chemistry letters.
[12] Charles D. McDermott,et al. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases , 1997, Clinical & Experimental Metastasis.
[13] D. Goeddel,et al. Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.
[14] W A Buurman,et al. Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.
[15] S. Nishimura,et al. Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[16] M. Ohashi,et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. , 1997, Life sciences.
[17] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.